Recorded fact · drug.label_indication
drug.label_indication for mavacamten|hypertrophic-cardiomyopathy
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 48b5c85e resolves to.
The record
| Fact id | 48b5c85e41897df351878325 |
|---|---|
| Entity | drug: mavacamten|hypertrophic-cardiomyopathy |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20250417 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
CAMZYOS ® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 91e2d3b7bf4baaad428a00d569584c2425bf3e1dbbb4880691079609daa4e7c1.
The value
{
"ingredient": "Mavacamten",
"conditionId": "hypertrophic-cardiomyopathy",
"conditionName": "Hypertrophic cardiomyopathy",
"matchedAlias": "hypertrophic cardiomyopathy",
"context": "indication",
"brand": "CAMZYOS",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "669c936b-3ee6-4e36-8a22-79dd11b1255b",
"labelEffectiveTime": "20250417",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: f716e18ba6ae4d5632ac2899be29011f86b7364d95143950b6cdbede4fb905b2.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.